Fingerprint
Dive into the research topics of 'Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D. Tap, Hans Gelderblom, Emanuela Palmerini, Jayesh Desai, Sebastian Bauer, Jean Yves Blay, Thierry Alcindor, Kristen Ganjoo, Javier Martín-Broto, Christopher W. Ryan, David M. Thomas, Charles Peterfy, John H. Healey, Michiel van de Sande, Heather L. Gelhorn, Dale E. Shuster, Q. Wang, Antoine Yver, Henry H. Hsu, Paul S. Lin
Research output: Contribution to journal › Article › peer-review
253
Scopus
citations